Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

被引：154

作者：

Chia, Puey Ling ^{[1
]}

Mitchell, Paul ^{[1
]}

Dobrovic, Alexander ^{[2
,3
,4
]}

John, Thomas ^{[1
,2
,4
]}

机构：

[1] Olivia Newton John Canc & Wellness Ctr, Dept Med Oncol, Heidelberg, Vic, Australia

[2] Austin Hlth, Ludwig Inst Canc Res, Melbourne, Vic, Australia

[3] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia

[4] La Trobe Univ, Sch Canc Med, Bundoora, Vic 3086, Australia

来源：

CLINICAL EPIDEMIOLOGY | 2014年 / 6卷

关键词：

anaplastic lymphoma kinase (ALK); gene rearrangements; lung cancer; kinase inhibitors; lung adenocarcinoma; ANAPLASTIC LYMPHOMA KINASE; POLYMERASE CHAIN-REACTION; EML4-ALK FUSION VARIANTS; ACQUIRED-RESISTANCE; NEVER-SMOKERS; MOLECULAR CHARACTERIZATION; BRAF GENE; EGFR; MUTATIONS; IMMUNOHISTOCHEMISTRY;

D O I：

10.2147/CLEP.S69718

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations. In this review, we will discuss the prevalence and clinical characteristics of ALK+ lung cancer, current treatment options, and future directions in the management of this subset of NSCLC patients.

引用

页码：423 / 432

页数：10

共 102 条

[61] Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 [J].

Ohashi, Kadoaki ;

Sequist, Lecia V. ;

Arcila, Maria E. ;

Moran, Teresa ;

Chmielecki, Juliann ;

Lin, Ya-Lun ;

Pan, Yumei ;

Wang, Lu ;

de Stanchina, Elisa ;

Shien, Kazuhiko ;

Aoe, Keisuke ;

Toyooka, Shinichi ;

Kiura, Katsuyuki ;

Fernandez-Cuesta, Lynnette ;

Fidias, Panos ;

Yang, James Chih-Hsin ;

Miller, Vincent A. ;

Riely, Gregory J. ;

Kris, Mark G. ;

Engelman, Jeffrey A. ;

Vnencak-Jones, Cindy L. ;

Dias-Santagata, Dora ;

Ladanyi, Marc ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (31) :E2127-E2133

[62] Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC [J].

Ou, S. -H. I. ;

Jaenne, P. A. ;

Bartlett, C. H. ;

Tang, Y. ;

Kim, D. -W. ;

Otterson, G. A. ;

Crino, L. ;

Selaru, P. ;

Cohen, D. P. ;

Clark, J. W. ;

Riely, G. J. .

ANNALS OF ONCOLOGY, 2014, 25 (02) :415-422

[63]

Ou SI, 2013, 15 WORLD C LUNG CANC

[64] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J].

Pao, W ;

Miller, VA ;

Politi, KA ;

Riely, GJ ;

Somwar, R ;

Zakowski, MF ;

Kris, MG ;

Varmus, H .

PLOS MEDICINE, 2005, 2 (03) :225-235

[65] Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. [J].

Rizvi, Naiyer A. ;

Chow, Laura Quan Man ;

Borghaei, Hossein ;

Shen, Yun ;

Harbison, Christopher ;

Alaparthy, Suresh ;

Chen, Allen C. ;

Gettinger, Scott N. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[66] Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population [J].

Rodig, Scott J. ;

Mino-Kenudson, Mari ;

Dacic, Sanja ;

Yeap, Beow Y. ;

Shaw, Alice ;

Barletta, Justine A. ;

Stubbs, Hannah ;

Law, Kenny ;

Lindeman, Neal ;

Mark, Eugene ;

Janne, Pasi A. ;

Lynch, Thomas ;

Johnson, Bruce E. ;

Iafrate, A. John ;

Chirieac, Lucian R. .

CLINICAL CANCER RESEARCH, 2009, 15 (16) :5216-5223

[67] Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer [J].

Sanders, Heather R. ;

Li, Hai-Rong ;

Bruey, Jean-Marie ;

Scheerle, Jay A. ;

Meloni-Ehrig, Aurelia M. ;

Kelly, JoAnn C. ;

Novick, Constance ;

Albitar, Maher .

CANCER GENETICS, 2011, 204 (01) :45-52

[68] A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors [J].

Sasaki, Takaaki ;

Koivunen, Jussi ;

Ogino, Atsuko ;

Yanagita, Masahiko ;

Nikiforow, Sarah ;

Zheng, Wei ;

Lathan, Christopher ;

Marcoux, J. Paul ;

Du, Jinyan ;

Okuda, Katsuhiro ;

Capelletti, Marzia ;

Shimamura, Takeshi ;

Ercan, Dalia ;

Stumpfova, Magda ;

Xiao, Yun ;

Weremowicz, Stanislawa ;

Butaney, Mohit ;

Heon, Stephanie ;

Wilner, Keith ;

Christensen, James G. ;

Eck, Michel J. ;

Wong, Kwok-Kin ;

Lindeman, Neal ;

Gray, Nathanael S. ;

Rodig, Scott J. ;

Jaenne, Pasi A. .

CANCER RESEARCH, 2011, 71 (18) :6051-6060

[69] The biology and treatment of EML4-ALK non-small cell lung cancer [J].

Sasaki, Takaaki ;

Rodig, Scott J. ;

Chirieac, Lucian R. ;

Janne, Pasi A. .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) :1773-1780

[70] Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer [J].

Sequist, Lecia V. ;

Gettinger, Scott ;

Senzer, Neil N. ;

Martins, Renato G. ;

Jaenne, Pasi A. ;

Lilenbaum, Rogerio ;

Gray, Jhanelle E. ;

Iafrate, A. John ;

Katayama, Ryohei ;

Hafeez, Nafeeza ;

Sweeney, Jennifer ;

Walker, John R. ;

Fritz, Christian ;

Ross, Robert W. ;

Grayzel, David ;

Engelman, Jeffrey A. ;

Borger, Darrell R. ;

Paez, Guillermo ;

Natale, Ronald .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (33) :4953-4960

← 2 3 4 5 6 7 8 9 10 11 →